Skip to main content
. Author manuscript; available in PMC: 2021 Nov 28.
Published in final edited form as: Leukemia. 2021 May 28;35(10):2906–2916. doi: 10.1038/s41375-021-01284-4

Figure 1. Relative risk (and 95% CI) by active bone marrow dose for (a) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma, (d) multiple myeloma.

Figure 1

Solid blue line + symbols give the observed relative risk (and 95% CI), red line gives relative risk = 1, dashed green line the fitted linear relative risk model, with ERR/Gy taken from Table 1. Dose boundaries used for categories are 0, 0.005, 0.02, 0.10, 0.15, 0.20, 0.50, 0.75, 1.00, 2.00 Gy.